Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer

Ten of 23 patients with advanced measurable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF). The median duration of response is in excess of 7 months, and responding patients have lived significantly longer than patients with progressive disease (7.5+ months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent azotemia in 9% of patients.